Rituximab for the treatment of ANCA associated vasculitis. The future today?;Rituximab en el tratamiento de las vasculitis asociadas a ANCA: ¿el futuro hoy?

Reumatologia Clinica

Volumn 7, Issue SUPPL. 3, 2011, Pages

  Alba, Marco A ^a   Flores Suárez, Luis F ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

ANCA; Rituximab; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ARTICLE; DRUG EFFICACY; HUMAN; MORBIDITY; MORTALITY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; BIOLOGICAL THERAPY; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE; GRANULOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFECTION; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83255184995     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.10.006     Document Type: Article

References (76)

1. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides, Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
2. Fauci A.S., Haynes B.F., Katz P., Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
3. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
4. Nachman P.H., Hogan S.L., Jennette J.C., Falk R.J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
5. De Groot K., Harper L., Jayne D.R., Flores Suarez L.F., Gregorini G., Gross W.L., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670-680.
6. Matteson E.L., Gold K.N., Bloch D.A., Hunder G.G. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996, 101:129-134.
7. Flossmann O., Berden A., De Groot K., Hagen C., Harper L., Heijl C., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011, 70:488-494.
8. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994, 154:97-101.
9. Kumagai S., Kawano S., Atsumi T., Inokuma S., Okada Y., Kanai Y., et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 2005 May, 32:863-869.
10. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770.
11. Food and Drug Administration CfDEaR. 2011 [consultado 30 Abr 2011]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm.
12. Dorner T., Jacobi A.M., Lipsky P.E. B cells in autoimmunity. Arthritis Res Ther 2009, 11:247.
13. Popa E.R., Stegeman C.A., Bos N.A., Kallenberg C.G., Tervaert J.W. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999, 103:885-894.
14. Jennette J.C., Xiao H., Falk R.J. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006, 17:1235-1242.
15. Popa E.R., Franssen C.F., Limburg P.C., Huitema M.G., Kallenberg C.G., Tervaert J.W. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum 2002, 46:1894-1904.
16. Voswinkel J., Mueller A., Kraemer J.A., Lamprecht P., Herlyn K., Holl-Ulrich K., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006, 65:859-864.
17. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009, 60:1540-1547.
18. Ferraro A.J., Smith S.W., Neil D., Savage C.O. Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant 2008, 23:3030-3032.
19. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988, 7:711-717.
20. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
21. Golbin J.M., Specks U., Targeting B lymphocytes as therapy for ANCA-associated vasculitis. Rheum Dis Clin North Am 2007, 33:741-754.
22. Walsh M., Jayne D. Targeting the B cell in vasculitis. Pediatr Nephrol 2009, 24:1267-1275.
23. Bingham C.O.3rd, Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
24. Henes J.C., Fritz J., Koch S., Klein R., Horger M., Risler T., et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007, 26:1711-1715.
25. Jones R.B., Ferraro A.J., Chaudhry A.N., Brogan P., Salama A.D., Smith K.G., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168.
26. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
27. Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262-268.
28. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180-187.
29. Lovric S., Erdbruegger U., Kumpers P., Woywodt A., Koenecke C., Wedemeyer H., et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009, 24:179-185.
30. Omdal R., Wildhagen K., Hansen T., Gunnarsson R., Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005, 34:229-232.
31. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008, 35:2017-2023.
32. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
33. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006, 45:1432-1436.
34. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
35. Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840.
36. Staines K.S., Higgins B. Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:76-80.
37. Tamura N., Matsudaira R., Hirashima M., Ikeda M., Tajima M., Nawata M., et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007, 46:409-414.
38. Geetha D., Seo P., Specks U., Fervenza F.C. Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 2007, 7:2821-2825.
39. Ooka S., Maeda A., Ito H., Omata M., Yamada H., Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod Rheumatol 2009, 19:80-83.
40. Sharma A., Kumar S., Wanchu A., Lal V., Singh R., Gupta V., et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. Clin Rheumatol 2010, 29:107-110.
41. Brihaye B., Aouba A., Pagnoux C., Vignaux O., Le Hello C., Guillevin L. Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. Presse Med 2008, 37:412-415.
42. Ferraro A.J., Day C.J., Drayson M.T., Savage C.O. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005, 20:622-625.
43. Huerva V., Sanchez M.C., Traveset A., Jurjo C., Ruiz A. Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea 2010, 29:708-710.
44. Onal S., Kazokoglu H., Koc A., Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008, 16:230-232.
45. Khan A., Lawson C.A., Quinn M.A., Isdale A.H., Green M.J. Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab. Int J Rheumatol 2010, 2010:846063.
46. Mansfield N., Hamour S., Marie-Habib A., Tarzi R., Levy J., Griffith M., et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011 Mar 17, E pub.
47. Martinez Del Pero M., Chaudhry A., Jones R.B., Sivasothy P., Jani P., Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009, 34:328-335.
48. Rees F., Yazdani R., Lanyon P. Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol 2011, 30:1241-1245.
49. Cheung C.M., Murray P.I., Savage C.O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.
50. Jose R.J., Chrysochou C., Shurrab A.E., New D., Wood G.N. Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis. Scand J Urol Nephrol 2010, 44:459-462.
51. Kowalewska B., Szechinski J., Roszkowska E. Wegener's granulomatosis effectively treated with rituximab: a case study. Pol Arch Med Wewn 2008, 118:381-385.
52. Asamiya Y., Moriyama T., Takano M., Iwasaki C., Kimura K., Ando Y., et al. Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. Intern Med 2010, 49:1587-1591.
53. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540-548.
54. Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006, 65:853-858.
55. Guerry M.J., Brogan P., Bruce I.N., D'Cruz D.P., Harper L., Luqmani R., et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2011 May 25, E pub.
56. Flores-Suárez L.F. RTX for WG: clinical observations in a heterogeneous population with predominant granulomatous disease. Clin Exp Immunol 2011, 164(Suppl 1):54.
57. Hiemstra T.F., Walsh M., Mahr A., Savage C.O., De Groot K., Harper L., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010, 304:2381-2388.
58. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
59. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., Ducroix J.P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803.
60. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., De Groot K., Gross W., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
61. Jones R.B., Smith R., Guerry M.-J., Laurino S., Catapano F., Chaudhry A., et al. Protocolized versus non-protocolized RTX treatment for refractory ANCA-AAV. Clin Exp Immunol 2011, 164(Suppl 1):58.
62. Niles J., McGrath M., Laliberte K. Continuous RTX therapy for ANCA-AAV. Clin Exp Immunol 2011, 164(Suppl 1):62.
63. Specks U., Stone J.H. Long-term effi cacy and safety results of the RAVE trial. Clin Exp Immunol 2011, 164(Suppl 1):65.
64. Hellmich B., Flossmann O., Gross W.L., Bacon P., Cohen-Tervaert J.W., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
65. Rutgers A., Kallenberg C.G. Refractory vasculitis. Autoimmun Rev 2011, 10:702-706. E pub 2011 May 4.
66. Avshovich N., Boulman N., Slobodin G., Zeina A.R., Rosner I., Rozenbaum M. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J 2009, 11:566-568.
67. Kaushik V.V., Reddy H.V., Bucknall R.C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006, 65:1116-1117.
68. Sanchez-Cano D., Callejas-Rubio J.L., Ortego-Centeno N. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008, 14:92-93.
69. Callejas Rubio J.L., Camps M.T., Garcia-Hernandez F. Treatment with rituximab of autoimmune disease: results from AADEA's registry. Med Clin (Barc) 2008, 130:79.
70. Lamprecht P., Wieczorek S., Epplen J.T., Ambrosch P., Kallenberg C.G. Granuloma formation in ANCA-associated vasculitides. APMIS Suppl 2009, 127:32-36.
71. Grillo-Lopez A.J. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 2003, 3:767-779.
72. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
73. van der Kolk L.E., Baars J.W., Prins M.H., van Oers M.H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257-2259.
74. Helena M., Jones R.B., Smith R.M., Catapano F., Chaundhry A.N., Jayne D.R.W. Hypogammaglobulinaemia and infections following RTX therapy for systemic vasculitis and SLE. Clin Exp Immunol 2011, 164(Suppl 1):59.
75. Harris H.E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008, 47:224-225.
76. White R.P., Abraham S., Singhal S., Manji H., Clarke C.R. Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41:826-827.